Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:tafamidis
|
| gptkbp:associatedWith |
gptkb:Vyndaqel
|
| gptkbp:ATCCode |
N07XX10
|
| gptkbp:chemicalClass |
benzoxazole derivative
|
| gptkbp:FDAapprovalDate |
2019-05-03
|
| gptkbp:form |
capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vyndamax
|
| gptkbp:indication |
transthyretin amyloid cardiomyopathy
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketedIn |
gptkb:United_States
|
| gptkbp:mechanismOfAction |
transthyretin stabilizer
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:tafamidis
|
| gptkbp:bfsLayer |
8
|